The latest update is out from Novavax ( (NVAX) ).
Novavax, a leader in vaccine development, announced the FDA’s removal of a clinical hold on their COVID-19-Influenza combination and influenza vaccine trials, paving the way for Phase 3 trials to commence. This decision follows Novavax’s successful response to safety concerns, confirming no link between a severe adverse event and their vaccine. The company is set to resume trial activities swiftly, reinforcing its commitment to advancing innovative vaccines.
For a thorough assessment of NVAX stock, go to TipRanks’ Stock Analysis page.
